Monthly Prescribing Reference

Retevmo Gets Traditional Approval for RET-Driven Medullary Thyroid Cancer

Median progression free survival in the selpercatinib group was not reached and was 16.8 months in the cabozantinib/vandetanib group. The Food and Drug Administration ...
Nasdaq

- Data demonstrated durable objective responses across both the RET fusion-positive NSCLC and RET-altered thyroid cancer patient cohorts

"Patients living with RET fusion-driven NSCLC represent an underserved population in need of tailored therapies that work against this targetable alteration," said Alexander Drilon, M.D.2, chief of ...
Monthly Prescribing Reference

Retevmo Approved for RET-Driven Solid Tumors, NSCLC

The approvals were based on data from the LIBRETTO-001 trial. The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo ® (selpercatinib) for adults with locally advanced or ...
Seeking Alpha

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

Retevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with CNS activity. Retevmo may affect both tumor cells and healthy ...